Title: Results of VIRAGE trial: a randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer
Speaker: Dr. Manel Cascalló, CEO of Theriva Biologics

About Dr. Manel Cascalló
Dr. Manel Cascalló, PhD, is the General Director for Europe at Theriva Biologics and former CEO of VCN Biosciences, a pioneering company in oncolytic virotherapy. He holds a Ph.D. in Molecular Biology from the University of Barcelona and completed advanced training at MD Anderson Cancer Center in the United States.

With more than 12 years of leadership experience in biotech, Dr. Cascalló is a recognized expert in the clinical development of oncolytic adenoviruses. He has authored numerous peer-reviewed publications and is the inventor of several patents that have advanced viral therapies for hard-to-treat cancers. His work has been instrumental in the development of VCN-01, an innovative oncolytic virus currently in clinical trials for pancreatic cancer.

Dr. Cascalló also serves as an independent expert for the European Medicines Agency (EMA), contributing to regulatory science and translational research. His career reflects a strong commitment to bringing cutting-edge science closer to patients.

📌 Join the seminar via Zoom: https://us06web.zoom.us/j/88680356896
Click here to connect

Please share this event with colleagues and contacts who may be interested in attending.